Sarepta Therapeutics, Inc.

NASDAQ (USD): Sarepta Therapeutics, Inc. (SRPT)

Last Price

146.35

Today's Change

+0.74 (0.50%)

Day's Change

144.49 - 147.33

Trading Volume

1,021,023

Overview

Market Cap

13 Billion

Shares Outstanding

94 Million

Avg Volume

1,908,744

Avg Price (50 Days)

136.38

Avg Price (200 Days)

118.00

PE Ratio

332.61

EPS

0.44

Earnings Announcement

31-Jul-2024

Previous Close

145.61

Open

145.39

Day's Range

144.49 - 147.33

Year Range

55.25 - 173.25

Trading Volume

1,021,023

Price Change Highlight

1 Day Change

0.51%

5 Day Change

-0.79%

1 Month Change

-8.94%

3 Month Change

25.13%

6 Month Change

20.90%

Ytd Change

52.12%

1 Year Change

40.06%

3 Year Change

111.76%

5 Year Change

1.13%

10 Year Change

568.88%

Max Change

275.26%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment